Publication:
A case with new-onset neuromyelitis optica spectrum disorder following COVID-19 mRNA BNT162b2 vaccination

dc.contributor.coauthorAfşar, Nazire
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentGraduate School of Health Sciences
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorBuluş, Eser
dc.contributor.kuauthorÇalışkan, İlay
dc.contributor.kuauthorPolat-Altıntaş, Sevgi
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF HEALTH SCIENCES
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:30:25Z
dc.date.issued2022
dc.description.abstractIntroduction: In the midst of the coronavirus disease of 2019 pandemic, active immunization by effective vaccination gained utmost importance in terms of global health. The messenger RNA (mRNA) vaccines are novel strategies requiring clinical surveillance for adverse events. Case Report: We report a 43-year-old previously healthy female with an optic neuritis attack 24 hours following immunization with the second dose of coronavirus disease of 2019 mRNA BNT162b2 vaccine. A second transverse myelitis attack together with an elevated anti-AQP-4 antibody titer confirmed the diagnosis of neuromyelitis optica spectrum disorder. Conclusion: Our case identifies the BNT162b2 vaccine as a possible trigger for neuromyelitis optica spectrum disorder. This rare and potentially coincidental event has no implications for vaccine administration practices. However, further research is needed to elucidate the effects of mRNA vaccines on humoral and cell-mediated immunity.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue3
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume27
dc.identifier.doi10.1097/NRL.0000000000000420
dc.identifier.eissn2331-2637
dc.identifier.issn1074-7931
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-85128313597
dc.identifier.urihttps://doi.org/10.1097/NRL.0000000000000420
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12235
dc.identifier.wos790876000012
dc.keywordsNMOSD
dc.keywordsBNT162b2
dc.keywordsCovid-19
dc.keywordsmRNA vaccine
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofNeurologist
dc.subjectClinical neurology
dc.titleA case with new-onset neuromyelitis optica spectrum disorder following COVID-19 mRNA BNT162b2 vaccination
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorÇalışkan, İlay
local.contributor.kuauthorBuluş, Eser
local.contributor.kuauthorPolat-Altıntaş, Sevgi
local.publication.orgunit1GRADUATE SCHOOL OF HEALTH SCIENCES
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1Research Center
local.publication.orgunit2KUTTAM (Koç University Research Center for Translational Medicine)
local.publication.orgunit2School of Medicine
local.publication.orgunit2Graduate School of Health Sciences
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscovery91bbe15d-017f-446b-b102-ce755523d939
relation.isParentOrgUnitOfPublication4c75e0a5-ca7f-4443-bd78-1b473d4f6743
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery4c75e0a5-ca7f-4443-bd78-1b473d4f6743

Files